The phase III TRITON3 trial investigated rucaparib vs physician-selected single-agent therapy in patients with metastatic castration-resistant prostate cancer and certain genetic alterations in terms of progression-free survival. These findings were published by Fizazi et al in The New England Journal of Medicine and also presented at the 2023 ASCO Genitourinary Cancers Symposium.
